在免疫抑制患者中没有皮肤病变的胃腺卡波西肉瘤
Ana Rita Ambrósio1, Catarina Bico Filipe2, Telma Costa Cabral1
1Internal Medicine, Hospital Beatriz Ângelo, Loures, PRT.
Cureus
|February 12, 2026
概括
阴性卡波西肉瘤 (KS),一种人类疹病毒8 (HHV-8) 感染,可以影响内部器官. 这一案例突显了免疫抑制,HIV阴性患者的胃肠癌,强调了在类似的临床场景中需要考虑这一点.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 胃肠病学 胃肠病学
背景情况:
- 卡波西肉瘤 (KS) 是一种与人类疹病毒8 (HHV-8) 相关的血管增殖性瘤.
- 胃肠道参与的KS可以表现在各种器官,包括胃和十二指肠.
- 免疫抑制,无论是由于艾滋病毒还是药物治疗,都是KS发展的主要危险因素.
研究的目的:
- 报告一种罕见的阴性卡波西肉瘤病例,在艾滋病毒阴性患者中涉及胃关节.
- 强调在接受医疗治疗的免疫抑制个体中考虑胃肠道KS的重要性.
主要方法:
- 一名53岁的男性患者患有膜性病,出现了胃肠道症状.
- 腹腔皮层CT和上胃肠内镜进行了诊断评估.
- 活检和免疫组织化学证实了卡波西肉瘤的诊断.
主要成果:
- 患者表现出包括腹痛,早,厌食症和发烧在内的症状.
- 扫描显示了中腔和周围胰腺淋巴结的扩大,并出现了死的变化.
- 内镜活检证实了具有显著胃口关节病变的阴性卡波西肉瘤.
结论:
- 胃肠道卡波西肉瘤应考虑在因药物治疗而导致免疫抑制的HIV阴性患者的差异诊断中.
- 这一案例凸显了iatrogenic KS可能表现为显著的胃肠道病理.
- 早期识别和诊断对于免疫受损患者的KS适当管理至关重要.
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.4K
Patient-centered Care
3.1K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
Drug Dosing: Geriatric Patients
278
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacodynamics in Geriatric Patients: Effects of Age
241
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
241
Pharmacokinetics in Pediatric Patients: Drug Excretion
277
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
277


